Abstract:Purpose/Objective(s) Mucosal melanoma of the head and neck is a rare and deadly disease. The optimal treatment for mucosal melanoma remains uncertain, and there is no consensus on the most effective treatment approach, including the extent of surgical resection, the use of adjuvant therapy, and the role of immunotherapy. Current controversies and unknowns about disease treatment and outcomes stem from the rarity of mucosal melanoma, the lack of large-scale clinical trials, and the heterogeneity of the disease. This study aims to determine the survival benefit of immunotherapy, surgery and radiation in setting of mucosal melanoma. Materials/Methods We extracted data from NCDB database with histology codes (ICD-O 2 melanoma codes M872–M879) for patients with mucosal melanoma diagnosed from year 2000-2020 with a total sample size 3937. The patients’ characteristics were summarized by median and interquartile range (IQR) for a continuous variable and by frequency and percentage for a categorical variable. We considered the different combinations of treatments in terms of surgery, chemotherapy, radiation therapy, and immunotherapy. The outcome variables are (1) time to death since diagnosis, and (2) death. Kaplan-Meier survival estimates were used. The log-rank test was employed to compare the survival distributions of the different treatment groups. Cox Proportional Hazard Regression model was performed to evaluate the association between the treatment combinations and survival outcome, adjusting the clinical and demographic variables (e.g., sex, age, stage of cancer). Hazard ratio (HR) and 95% confidence interval (CI) were reported. Mortality rate for each treatment combination was also reported, and the multiple logistic regression model was used to examine the effect of different treatment on mortality. Results The median overall survival (OS) time for all patients diagnosed with mucosal melanoma was 25.7 months. Among them, 50.1% were males, 9.4% younger than 50 years old and 50.6% older than 70, 88.7% white, and 57.6% with Medicare. Cox proportional hazard model showed that the survival time is significantly associated with the following factors: age group 60-70 (HR 1.25, 95%CI [1.06, 1.48]) and >70 (HR 1.83, 95%CI [1.56, 2.13]) comparing with age group <50. Male sex increased the risk of death (HR 1.13, 95%CI[1.04, 1.22]). Surgery decreased the risk of death (HR 0.49, 95%CI [0.44, 0.55]). The use of radiation and immunotherapy had no association with survival. Chemotherapy increased the risk of death (HR 1.33, 95%CI [1.18,1.51]), and was associated with more advanced age and high tumor stage. The multiple logistic regression model showed similar impact of these factors on mortality. Conclusion Treatment paradigms for mucosal melanoma vary widely. Local therapy remains important for improved survival. Further analyses should be done to explore the benefits of multi-modality treatment.

Mucosal melanoma of the head and neck: a retrospective analysis of 34 cases in Japan

Clinical outcomes and patterns of failure of head and neck mucosal melanoma treated with multiple treatment modalities

Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France

Transoral surgery for superficial head and neck cancer: National Multi‐Center Survey in Japan

Genetic Analysis of Melanoma Types Using Japanese Genomic Database

Outcomes of Primary Mucosal Melanoma Originated from Sinonasal Tract

Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: implications for systemic therapy

Current management of mucosal melanoma of the head and neck

Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry

Local and disease control for nasal melanoma treated with radiation and concomitant anti-programmed death 1 antibody

Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma.

Clinical Presentation, Systemic Therapy and Prognosis of Mucosal Melanoma, A Study of 463 Consecutive Cases

Characteristics and prognosis of primary mucosal melanoma of nasal cavity and paranasal sinuses: a clinical analysis of 94 patients

Subsite-specific trends in mid- and long-term survival for head and neck cancer patients in Japan: A population-based study

Clinical presentation, histology and prognosis of mucosal melanoma in ethnic Chinese: A study of 212 consecutive cases

Adjuvant Therapy with Immune Checkpoint Inhibitors after Carbon Ion Radiotherapy for Mucosal Melanoma of the Head and Neck: A Case-Control Study

Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study

Local Therapy in the Management of Mucosal Melanoma: An NCDB Analysis

A multicenter retrospective study on neck dissection and adjuvant radiotherapy with transoral surgery for hypopharyngeal squamous cell carcinoma

Definitive radiotherapy for nasopharyngeal carcinoma in Japan: analysis of cases in the National Head and Neck Cancer Registry from 2011 to 2014

Clinical Experience from a Single Italian Center